Donald Trump’s tariff war is too much for his otherwise steadfast ally Senator Ron Johnson, who compared the decision to ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

So, again, I just can't predict where this all goes, but I'm concerned. I don't know what else I can really say,” Johnson said ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Winter depression can take a toll on your mind and body. Local health experts say depression is something you should take seriously. Jessica Bowman speaks with a psychiatric nurse practitioner about ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common treatment for depression, but they don’t work for ...

"Treatment-resistant depression can be very complicated ... Ph.D., Global Therapeutic Area Head, Neuroscience, Johnson & Johnson Innovative Medicine, said in a statement. "Spravato is now available as ...